Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency

Treatment with investigational DNASE1L3 analog NTR-441, which degrades neutrophil extracellular traps (NETs), resulted in rapid clinical improvement in a patient with treatment-refractory SLE

Results provide first human proof-of-concept that enzymatic NET degradation may address a key driver of disease activity in SLE, with broader implications for other NET-driven autoimmune and inflammatory diseases

Observations from this single-patient compassionate-use treatment support Neutrolis’ broader exDNASE™ platform, including NTR-1011, now advancing in clinical studies in SLE and rheumatoid arthritis (RA)

Excerpt from the Press Release:

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) — Neutrolis, Inc., a biotechnology company pioneering therapies that target neutrophil extracellular traps (NETs), today announced a clinical report published in The New England Journal of Medicine demonstrating that administration of NTR-441, an investigational DNASE1L3 analog, resulted in rapid clinical improvement in a patient with severe, treatment-refractory SLE and hypocomplementemic urticarial vasculitis caused by congenital DNASE1L3 deficiency.

The publication, titled “Targeted Degradation of NETs in Lupus with DNASE1L3 Deficiency,” reported rapid clinical and pharmacodynamic effects following weekly intravenous administration of NTR-441 in a 16.5-year-old patient whose long-standing disease, including recurrent vasculitic rash, polyarthritis, episcleritis, inflammatory bowel disease, autoimmune hepatitis and persistent inflammation, had not achieved sustained remission despite extensive prior immunosuppressive therapy. The patient’s disease manifestations began at 1.5 years of age, and genetic testing at age 11 confirmed a homozygous loss-of-function DNASE1L3 variant as the cause.

Clinical symptoms resolved within six hours of the first infusion of NTR-441. A transient recurrence of rash and episcleritis occurred within 24 hours and subsequently improved.

Click the button below to read the entire Press Release:

Continue Reading The Press Release